NEW YORK and LEAMINGTON, Ontario, July 28, 2022 (GLOBE NEWSWIRE) –PRESS RELEASE– Tilray Brands, Inc.(Nasdaq: TLRY; TSX: TLRY), a global cannabis-lifestyle and consumer packaged goods company today reported financial results for the fourth quarter and full fiscal year ended May 31, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated, and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”).
Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer, stated, “Over the past year, we have accelerated the optimization of our operations and sharpened execution against our most profitable core business opportunities in medical, adult-use, wellness, and beverage-alcohol across Canada, Europe, and the U.S. At the same time, we accelerated our growth potential through tactical execution and strategic initiatives that enable accelerated revenue growth through improved cultivation, brand building, and distribution. These actions should also contribute to bottom-line performance improvement through production efficiencies and cost reductions. The outcome of this work is that we have driven top line growth across our markets, significantly improved our operating performance, and strengthened our balance sheet.”
He continued, “We are confident that our proactive steps to plan for the evolution of the cannabis business in each of our markets has positioned Tilray Brands to be at the forefront of the industry on a global basis while delivering profitability and driving shareholder value.”
Financial Highlights – 2022 Fiscal Fourth Quarter1
Net revenue grew 8% to $153.3 million during the fourth quarter from $142.2 million in the prior year quarter. On a constant currency basis, net revenue increased 14.5%.Net loss of $457.8 million during the fourth quarter compared to net income of $33.6 million in the prior year quarter. Net loss in the fiscal 2022 fourth quarter includes a non-cash impairment of $395.0 million primarily impacting inventory, goodwill and other intangible assets. The impact was related to changes in market opportunities causing a shift in our strategic priorities, and market conditions inclusive of higher rates of borrowing and lower foreign exchange rates.Adjusted EBITDA of $11.5 million, marking the company’s 13th consecutive quarter of positive Adjusted EBITDA.
Financial Highlights- 2022 Fiscal Year
Net revenue increased 22% to $628.4 million during fiscal 2022 from $513.1 million in the prior fiscal year. The increase was driven by 17.9% growth in cannabis net revenue to $237.5 million, a 150.0% increase in beverage alcohol net revenue of $71.5 million, and a 928.8% increase in wellness net revenue to $59.6 million. On a constant currency basis, net revenue increased by 29%.Net loss of $434 million in fiscal 2022 includes the non-cash impairment of $395.0 million in the fourth quarter (discussed above).Adjusted EBITDA increased 17.8% to $48.0 million in fiscal year 2022 from $40.8 million in the prior fiscal year.Ended the year with a strong balance sheet and liquidity, including cash and cash equivalents of $415.9 million.
Cost-Saving Synergies and Strengthened Balance Sheet
Since the closing of the Tilray-Aphria transaction, the company has delivered $85 million in cost synergies, exceeding its original target of delivering $80 million of cost savings by the end of fiscal year 2023. These synergies are due to consolidation in key areas of cultivation and production, cannabis and product purchasing, sales and marketing, and corporate expenses. The company has subsequently identified an additional $20 million of savings, and now expects to deliver a total of $100 million in cost synergies from the transaction by the end of fiscal year 2023.
Further, with the benefit of an additional $80 million of shared cost savings, synergies and financial benefits over the next two years associated with the HEXO transaction, management expects that Tilray Brands will be free cash flow positive in its business units in fiscal year 2023.
Upside Potential of HEXO Transaction
Tilray Brands’ acquisition of HEXO Corp.’s senior secured convertible note, on highly favorable terms, closed on July 12, 2022, bringing immediate accretion to the company and facilitating collaboration and the sharing of best practices that will help Tilray Brands to drive ongoing international expansion and take advantage of the opportunities expected to come with federal legalization in the U.S. In addition, due to significant operating efficiencies, the companies expect to deliver a total of $80 million of shared cost savings over the next two years.
Highlights of Strategic Growth Actions in Fiscal 2022
August ’21 – Tilray Acquires Majority Position in Amended MedMen Convertible Notes November ’21 – Tilray’s SweetWater Brand Enters Spirits Category Through New Ready-To-Drink Cocktail Now Available in the United States December ’21 – Tilray Strengthens Strategic Position in the U.S. with Acquisition of Breckenridge Distillery December ’21 – SweetWater Brewing announced the acquisition of Alpine Beer company and Green Flash Brewing companyJanuary ’22 – Manitoba Harvest Launches 2022 Wellness Boost CampaignFebruary ’22 – SweetWater Brewing company Expands Distribution Across California February ’22 – SweetWater Brewing company Continues Rapid Expansion with Distribution Rollout Across Washington & Oregon April ’22 – SweetWater Brewing company celebrated 25th anniversary and hosted 420 music Festival in Atlanta, Georgia with 75 thousand festival goersApril ’22 – Manitoba Harvest Enters Exclusive Partnership with Whole Foods MarketApril ’22 – Breckenridge Distillery Takes Home Two Double Gold and One Gold Medal at the 2022 San Francisco World Spirits CompetitionApril ’22 – Breckenridge Distillery Launches New Collectors Art Series with Denver Artist Alexandrea Pangburn
June ’21 – Tilray Launches New Medical Cannabis Brand, Symbios June ’21 – Tilray Launches Canadian Craft Cannabis Brand, Broken Coast, in the U.S. with Broken Coast Lager August ’21 – Tilray Medical Launches New Medical Cannabis Edibles in Canada October ’21 – Tilray Strengthens Leadership Position in Canada with new addition of Blair MacNeil, President of Canada October ’21 – Tilray Expands Distribution across Canada with Great North Distributors December ’21 – Launch of Tilray’s Fast-Acting Oral Strips Highlights Commitment to Medical Cannabis Innovation and Patient Care March ’22 – Good Supply Brand Expands Its Award-Winning Cannabis Portfolio with Hash Bats™; A New ‘Hard-Hitting’ Infused Pre-Roll March ’22 – Solei Brand Launches New Wellness Product for Nighttime Use April ’22 – Solei Brand Launches the First Cannabis Edible Available in Quebec April ’22 – Tilray Brands hosts sold-out ‘Holy Smokes’ 420 Budtender event in TorontoMay ’22 – Good Supply Brand Expands High-Potency Cannabis Portfolio with Launch of Liquid Wax Vapes and New Exclusive Strains
Europe and International:
July ’21 – Tilray’s Aphria RX GmbH Completes First Harvest and Delivery of Medical Cannabis Grown in Germany October ’21 – Tilray Launches Medical Cannabis in LuxembourgNovember ’21 – Tilray Expands Medical Cannabis Footprint in Malta January ’22 – Tilray Expands Medical Cannabis Product Offering in Australia February ‘22 – Tilray Brands Consolidates its Global Medical Offering into Tilray Medical, a Comprehensive Portfolio of Brands and Products February ’22 – Tilray Launches Medical Cannabis Products in Malta March ’22 – Tilray Medical Expands Offering in Malta and Launches First Medical Cannabis Oil Products in Market May ’22 – Announced the launch of CBD lifestyle brand, POLLEN, on Amazon UK ]]>